A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Edrul
Synonyms :
Muzolimina, muzolimine, Muzoliminum
Class :
Cardiovascular agent, Antihypertensive, Diuretic, High Ceiling Loop diuretic, Pyrazolone derivative
Brand Name :
Edrul
Synonyms :
Muzolimina, muzolimine, Muzoliminum
Class :
Cardiovascular agent, Antihypertensive, Diuretic, High Ceiling Loop diuretic, Pyrazolone derivative
Dosage Forms & StrengthsÂ
TabletÂ
5 mgÂ
10 mgÂ
25 mgÂ
30 mgÂ
50 mgÂ
100 mgÂ
200 mgÂ
500 mgÂ
It is indicated for the management of edema in hypertensive patients
The usual recommended dose is 20-40 mg via oral single dose per day
Dose Adjustments
Limited data is available
Safety and efficacy are not seen in pediatricsÂ
Refer to the adult dosingÂ
NSAIDs may diminish the diuretic effect of loop diuretics
NSAIDs may diminish the diuretic effect of loop diuretics
NSAIDs may diminish the diuretic effect of loop diuretics
NSAIDs may diminish the diuretic effect of loop diuretics
NSAIDs may diminish the diuretic effect of loop diuretics
may decrease the diuretic effect of loop diuretics
may decrease the diuretic effect of nonsteroidal anti-inflammatory agents
arsenic trioxide: they may enhance the hypotensive effect of loop diuretics
may decrease the diuretic effect when combined with loop diuretics
may increase the hypotensive effect
opioid agonists increase the toxicity of diuretics
opioid agonists increase the toxicity of diuretics
amikacin liposome (oral inhalation)Â
they decrease the nephrotoxicity of liposomal amikacin oral inhalation
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
The administration of Loop Diuretics may intensify the hyponatremic impact of desmopressin
The use of Loop diuretics may increase the QTc-prolonging influence of promazine
may diminish the effects of indomethacin by pharmacodynamic antagonism
Loop Diuretics may increase the hypotensive effect of antihypertensive Agents
Loop Diuretics may increase the hypotensive effect of antihypertensive Agents
Loop Diuretics may increase the hypotensive effect of antihypertensive Agents
Loop Diuretics may increase the hypotensive effect of antihypertensive Agents
Loop Diuretics may increase the hypotensive effect of antihypertensive Agents
loop Diuretics may reduce the neuromuscular blocking effect of neuromuscular-Blocking Agents.
loop Diuretics may reduce the neuromuscular blocking effect of neuromuscular-Blocking Agents.
loop Diuretics may reduce the neuromuscular blocking effect of neuromuscular-Blocking Agents.
loop Diuretics may reduce the neuromuscular blocking effect of neuromuscular-Blocking Agents.
loop Diuretics may reduce the neuromuscular blocking effect of neuromuscular-Blocking Agents.
it increases the hypotensive effect of angiotensin II receptor blockers
it increases the hypotensive effect of angiotensin II receptor blockers
it increases the hypotensive effect of angiotensin II receptor blockers
it increases the hypotensive effect of angiotensin II receptor blockers
it increases the hypotensive effect of angiotensin II receptor blockers
may diminish the diuretic effect of loop diuretics
may diminish the diuretic effect of loop diuretics
may diminish the diuretic effect of loop diuretics
may diminish the diuretic effect of loop diuretics
may diminish the diuretic effect of loop diuretics
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the hypotensive effect of antihypertensive agents
may enhance the hypotensive effect of antihypertensive agents
may enhance the hypotensive effect of antihypertensive agents
may enhance the hypotensive effect of antihypertensive agents
may enhance the hypotensive effect of antihypertensive agents
loop diuretics may increase the risk of adverse effect of aminoglycosides
loop diuretics may increase the risk of adverse effect of aminoglycosides
loop diuretics may increase the risk of adverse effect of aminoglycosides
loop diuretics may increase the risk of adverse effect of aminoglycosides
loop diuretics may increase the risk of adverse effect of aminoglycosides
may enhance the hypotensive effect of angiotensin II receptor antagonist
may enhance the hypotensive effect of angiotensin II receptor antagonist
may enhance the hypotensive effect of angiotensin II receptor antagonist
may enhance the hypotensive effect of angiotensin II receptor antagonist
may enhance the hypotensive effect of angiotensin II receptor antagonist
may increase the risk of adverse effect of cardiac glycosides
may increase the risk of adverse effect of cardiac glycosides
may increase the risk of adverse effect of cardiac glycosides
may diminish the neuromuscular-blocking effect of neuromuscular blocking agentsÂ
may diminish the neuromuscular-blocking effect of neuromuscular blocking agentsÂ
may diminish the neuromuscular-blocking effect of neuromuscular blocking agentsÂ
may diminish the neuromuscular-blocking effect of neuromuscular blocking agentsÂ
may diminish the neuromuscular-blocking effect of neuromuscular blocking agentsÂ
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
May have an increased nephrotoxic effect when combined with Iodinated Agents
May have an increased nephrotoxic effect when combined with Iodinated Agents
May have an increased nephrotoxic effect when combined with Iodinated Agents
May have an increased nephrotoxic effect when combined with Iodinated Agents
They may diminish the absorption when combined with bile acid sequestrants
loop diuretics: they may increase the hypotensive effect when combined with antihypertensive drugs
loop diuretics: they may increase the hypotensive effect when combined with antihypertensive drugs
loop diuretics: they may increase the hypotensive effect when combined with antihypertensive drugs
may have an increased adverse/toxic effect when combined with aminoglycosides
neomycin/polymyxin B/bacitracin topical
may have an increased adverse/toxic effect when combined with aminoglycosides
may decrease the neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased hypotensive effect when combined with ACE inhibitors
may have an increased hypotensive effect when combined with ACE inhibitors
may have an increased hypotensive effect when combined with ACE inhibitors
may have an increased hypotensive effect when combined with ACE inhibitors
may have an increased hypotensive effect when combined with ACE inhibitors
loop diuretics: they may increase the toxic effect of mu-opioid receptor agonists
loop diuretics: they may increase the toxic effect of mu-opioid receptor agonists
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
muzolimine has the potential to enhance the excretion rate of abacavir, leading to a potential decrease in serum levels and a potential reduction in efficacy
may have an increased hypotensive effect when combined with ACE inhibitors
may have an increased hypotensive effect when combined with ACE inhibitors
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
loop Diuretics may increase the hypokalemic effect of dichlorphenamide
it May diminish the therapeutic effect of Loop Diuretics
it May diminish the therapeutic effect of Loop Diuretics
it May diminish the therapeutic effect of Loop Diuretics
it May diminish the therapeutic effect of Loop Diuretics
it May diminish the therapeutic effect of Loop Diuretics
loop Diuretics may enhance the hypokalemic effect of topiramate
empagliflozin increases the effect of hypotension of loop diuretics
may increase the hypokalemic effect of corticosteroids
loop diuretics may increase the risk of adverse effect of allopurinol
may reduce the rate of absorption of loop diuretics
may reduce the effect of loop diuretics
may reduce the effect of loop diuretics
may reduce the effect of loop diuretics
may reduce the effect of loop diuretics
may reduce the effect of loop diuretics
may increase the hypotensive effect of calcium channel blockers
hydrochlorothiazide/aliskirenÂ
may increase the hypotensive effect of antihypertensive agents
may increase the hypotensive effect of angiotensin receptor II blockers
may increase the hypokalemic effect of beta2 agonists
may increase the hypokalemic effect of beta2 agonists
may diminish the therapeutic effect of salicylates
may have an increased nephrotoxic effect when combined with iodinated agents
may have an increased nephrotoxic effect when combined with iodinated agents
may have an increased nephrotoxic effect when combined with iodinated agents
may have an increased nephrotoxic effect when combined with iodinated agents
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
may increase the hypokalemic effect when combined
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the hypokalemic effect of Beta2-Agonists
Beta2-Agonists: they may increase the hypokalemic effect of loop diuretics
Beta2-Agonists: they may increase the hypokalemic effect of loop diuretics
Beta2-Agonists: they may increase the hypokalemic effect of loop diuretics
The effectiveness of loop diuretics could be reduced by the presence of probenecid
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
may have an increased hypotensive effect when combined with angiotensin-converting enzyme inhibitors
mu-opioid receptor agonists: they may increase the toxic effect of loop diuretics
mu-opioid receptor agonists: they may increase the toxic effect of loop diuretics
canagliflozin: they may increase the hypotensive effect of loop diuretics
guanethidine: they may increase the hypotensive effect of loop diuretics
Loop Diuretics have the potential to increase the toxic or harmful impact of levosulpiride
loop diuretics may increase the nephrotoxic effect of cefotiam
The QTc-prolonging effect of bilastine may be enhanced by the concurrent use of loop diuretics
The harmful/toxic effect of aminoglycosides may be intensified by loop diuretics
neomycin/polymyxin B/bacitracin topical
The harmful/toxic effect of aminoglycosides may be intensified by loop diuretics
The harmful/toxic effect of aminoglycosides may be intensified by loop diuretics
The harmful/toxic effect of aminoglycosides may be intensified by loop diuretics
The harmful/toxic effect of aminoglycosides may be intensified by loop diuretics
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the hypokalemic effect of loop diuretics
may increase the hypokalemic effect of loop diuretics
may increase the hypokalemic effect of loop diuretics
may increase the hypokalemic effect of loop diuretics
may increase the hypokalemic effect of loop diuretics
choline magnesium trisalicylate
may decrease the diuretic effect of loop diuretics
nephrotoxicity associated with cisplatin may be enhanced with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
the hypotensive activities of muzolimine may be increased when used in conjunction with abaloparatide
muzolimine may augment the hypotensive activities of acebutolol
the therapeutic efficacy of muzolimine may be diminished when used concurrently with acemetacin
muzolimine has the potential to increase the excretion rate of acetaminophen, resulting in a potential decrease in serum levels and a potential decrease in efficacy
acetylsalicylic acid may lower the excretion rate of muzolimine, potentially leading to higher serum levels
muzolimine may raise the excretion rate of aclidinium, potentially resulting in a lower serum level and a potential decrease in efficacy
muzolimine may raise the excretion rate of acrivastine, potentially resulting in a lower serum level and a potential decrease in efficacy
muzolimine may raise the excretion rate of acyclovir, potentially resulting in a lower serum level and a potential reduction in efficacy
muzolimine may increase the excretion rate of zaleplon, potentially resulting in a lower serum level and a potential reduction in efficacy
muzolimine may increase the excretion rate of zanamivir, potentially resulting in a lower serum level and a potential reduction in efficacy
the risk or severity of CNS depression can be increased when muzolimine is combined with ziconotide
ziprasidone may increase the antihypertensive activities of muzolimine
zofenopril may increase the hypotensive activities of muzolimine
zolmitriptan may lower the antihypertensive activities of muzolimine
muzolimine may increase the excretion rate of zonisamide, potentially resulting in a lower serum level and a potential reduction in efficacy
zuclopenthixol may decrease the antihypertensive activities of muzolimine
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the nephrotoxic effect of angiotensin ii receptor blockers
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may increase the hypotensive effect of angiotensin-converting enzyme inhibitors
may increase the adverse/toxic effect of cardiac glycosides
may increase the adverse/toxic effect of cardiac glycosides
may increase the adverse/toxic effect of cardiac glycosides
loop diuretics have the potential to amplify the QTc-prolonging effect of dofetilide
The serum concentration of foscarnet can be enhanced by the concurrent use of loop diuretics
Actions and Spectrum:Â
Actions:Â
Muzolimine, which is suggested for hypertension treatment, is a diuretic that combines the high ceiling effect of loop diuretics with the prolonged action characteristic of thiazides. Despite having a distinct chemical structure from other loop diuretics, it exhibits similarities in its pharmacological profile. It is proposed to function as both a prodrug and an active metabolite found in the urine, potentially inhibiting NaCl reabsorption in Henle’s loop.Â
Spectrum:Â
The spectrum of muzolimine has been proven effective in the management of edema, mild hypertension, and essential hypertension.Â
Frequency not definedÂ
Severe neurological side effectsÂ
N/AÂ
Contraindication/Caution:Â
ContraindicationsÂ
CautionsÂ
Pregnancy consideration:Â Â
No data is available regarding the administration of the drug during pregnancy.Â
Breastfeeding warnings:Â Â
No data is available regarding the excretion of drug in breast milk.Â
Pregnancy category:Â
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: No data is available for the drug under this category.Â
Pharmacology:Â
Muzolimine, derived from dichlorobenzene, is a loop diuretic known for its delayed onset and prolonged duration of action. Initially employed in hypertension treatment, it was later removed from the market due to the emergence of severe neurological side effects.Â
Pharmacodynamics:Â
N/AÂ
Pharmacokinetics:Â
N/AÂ
Administration:Â
It is administered orally as a single dose and can be taken with or without food.Â
Patient information leafletÂ
Generic Name: muzolimineÂ
Pronounced: myoo-ZOL-uh-meenÂ
Why do we use muzolimine?Â
Muzolimine, classified as a high-ceiling loop diuretic, is a pyrazole diuretic initially prescribed for hypertension. However, its global withdrawal ensued due to the manifestation of severe neurological side effects.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
